Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $132.00 price target on the stock.
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition [Yahoo! Finance]
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Jefferies profit misses estimates as bond trading, equity underwriting weaken [Yahoo! Finance]
Jefferies profit falls on weaker bond trading, equity underwriting [Yahoo! Finance Canada]